The Effect of Different Prebiotics on Iron Absorption From High Dose Iron Supplements
Launched by SWISS FEDERAL INSTITUTE OF TECHNOLOGY · Dec 9, 2019
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
Prebiotics are defined as "microbial food supplements that beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacterial species already resident in the colon". Moreover, prebiotics are potential enhancers of iron absorption, via several mechanisms: a) increasing gastric residence time allowing for greater iron dissolution; b) stimulating enterocyte gene expression of proteins involved in iron absorption; c) stimulating enterocyte proliferation providing a greater surface for iron absorption; and d) stimulating SCFA production by ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female, 18 to 45 years old
- • SF concentrations ≤ 25 µg/L
- • Normal body Mass Index (18.5-24.9 kg/m2)
- • Body weight \<70 kg
- • Signed informed consent
- Exclusion Criteria:
- • Anaemia (Hb \< 11,7g/dL)
- • Any metabolic, gastrointestinal, kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement)
- • Continuous/long-term use of medication during the whole study (except for contraceptives),
- • Consumption of mineral and vitamin supplements within 2 weeks prior to 1st supplement administration, including pre- and/or probiotic supplements (excluding foods and beverages with life cultures such as yoghurt, raw milk cheese and kombucha)
- • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
- • Known difficulties with blood sampling
- • Use of antibiotics over the past month
- • Known hypersensitivity to iron supplements in the given amount, GOS, or lactose
- • Women who are pregnant or breast feeding
- • Women who intend to become pregnant during the course of the study
- • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
- • Known or suspected non-compliance, drug or alcohol (more than 2 drinks/day) abuse
- • Smokers (\> 1 cigarette per week)
- • Inability to follow the procedures of the study, e.g. due to language problems, self-reported psychological disorders, etc. of the participant
- • Enrolment of the investigator, his/her family members, employees and other dependent persons
About Swiss Federal Institute Of Technology
The Swiss Federal Institute of Technology (ETH Zurich) is a prestigious research university located in Switzerland, renowned for its cutting-edge scientific research and innovation. With a strong emphasis on interdisciplinary collaboration, ETH Zurich leverages its expertise in engineering, natural sciences, and technology to advance healthcare solutions through clinical trials. The institute is committed to improving patient outcomes and advancing medical knowledge by conducting rigorous, ethically-sound research that adheres to the highest standards of scientific integrity. Its distinguished faculty and state-of-the-art facilities position ETH Zurich as a leader in clinical research, fostering partnerships that bridge academia, industry, and healthcare institutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
Isabelle Herter-Aeberli, PhD
Study Director
Laboratory of Human Nutrition ETH Zürich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials